4-(3-fluoro-4-methyl-benzyl)-1-isopropyl-5-methyl-3-(6-O-ethoxycarbonyl-β-D-glucopyranos-1-yloxy)-1H-pyrazole | 922720-80-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3-fluoro-4-methyl-benzyl)-1-isopropyl-5-methyl-3-(6-O-ethoxycarbonyl-β-D-glucopyranos-1-yloxy)-1H-pyrazole
• 英文别名: ethyl [(2R,3S,4S,5R,6S)-6-[4-[(3-fluoro-4-methylphenyl)methyl]-5-methyl-1-propan-2-ylpyrazol-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl carbonate
• CAS: 922720-80-7
• 化学式: C₂₄H₃₃FN₂O₈
• 分子量: 496.533
• InChiKey: KBOLEFRIBPZQMU-VZWAGXQNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  4-((3-fluoro-4-methylphenyl)methyl)-1-isopropyl-5-methyl-1H-pyrazole-3-O-β-D-glucopyranoside 、 氯甲酸甲酯 在 2,4,6-三甲基吡啶 作用下， 以66%的产率得到4-(3-fluoro-4-methyl-benzyl)-1-isopropyl-5-methyl-3-(6-O-ethoxycarbonyl-β-D-glucopyranos-1-yloxy)-1H-pyrazole
  参考文献：
  名称：

  WO2008/87198

  摘要：

  公开号：

文献信息

• Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives
  申请人：Himmelsbach Frank

  公开号：US20070072813A1

  公开（公告）日：2007-03-29

  The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating the degeneration of pancreatic beta cells, for treating hyperinsulinemia and insulin resistance and diabetes type 1, in patients in need thereof by administering a pharmaceutical composition comprising a pyrazole-O-glycoside as defined in claim 1, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种预防或治疗代谢性疾病的方法，改善血糖控制，预防从糖耐量受损、胰岛素抵抗和/或代谢综合征进展到2型糖尿病，预防或治疗糖尿病并发症，减轻体重，预防或治疗胰岛β细胞退化，治疗高胰岛素血症和胰岛素抵抗以及1型糖尿病，方法是通过给需要的患者口服含有在权利要求1中定义的吡唑烷-O-糖苷或其前药或其药学上可接受的盐的药物组成物。
• PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE
  申请人：Pinnetti Sabine

  公开号：US20100317575A1

  公开（公告）日：2010-12-16

  The invention relates to a pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

  本发明涉及一种制药组合物，包括根据权利要求1所述的化合物（1）至（29）中选择的吡唑-O-葡萄糖苷衍生物，与至少一种第二治疗剂的组合物，该第二治疗剂适用于治疗或预防选择自1型糖尿病、2型糖尿病、糖耐量受损和高血糖等一个或多个疾病。此外，本发明还涉及预防或治疗代谢紊乱及相关疾病的方法。
• WO2007/14895
  申请人：——

  公开号：——

  公开（公告）日：——
• METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1912656A2

  公开（公告）日：2008-04-23
• [EN] METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES<br/>[FR] METHODES DE PREVENTION ET DE TRAITEMENT DE TROUBLES METABOLIQUES ET NOUVEAUX DERIVES PYRAZOLE-O-GLYCOSIDE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2007014895A2

  公开（公告）日：2007-02-08

  [EN] The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating the degeneration of pancreatic beta cells, for treating hyperinsulinemia and insulin resistance and diabetes type 1, in patients in need thereof by administering a pharmaceutical composition comprising a pyrazole-O-glycoside as defined in claim 1 , or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
  [FR] La présente invention concerne des méthodes permettant de prévenir ou de traiter des troubles métaboliques, d'améliorer le contrôle de la glycémie, d'empêcher la progression d'une diminution de la tolérance au glucose, d'une résistance à l'insuline et/ou d'un syndrome métabolique en diabète sucré de type 2, de prévenir ou de traiter les complications du diabète, de réduire le poids, de prévenir ou de traiter la dégénérescence des cellules bêta du pancréas, de traiter l'hyperinsulinémie, la résistance à l'insuline et le diabète de type 1 chez des patients nécessitant un tel traitement, lesquelles méthodes consistent à administrer au patient une composition pharmaceutique comprenant un pyrazole-O-glycoside tel que défini dans la revendication 1, ou un promédicament de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci.